Wall Street loves the companies listed below. So why do our Motley Fool CAPS members disagree? They've bestowed on these companies the lowest one- and two-star ratings, signaling their faith that the associated businesses will underperform the market.

So who's got it right? The professional class of analysts sitting in their paneled offices smoking stogies, or a motley crew of community investors pooling their best thoughts for others to share? We think we know who'll come out ahead. How about you?


CAPS Rating
(out of 5)

Wall Street Bullish Sentiment

Eastman Kodak (NYSE: EK)



Human Genome Sciences (Nasdaq: HGSI)



Nokia (NYSE: NOK)



Source: Motley Fool CAPS.

Now as much as we love our CAPS community, don't sell these companies short just because they've garnered the lowest ratings. And don't go long just because Wall Street says to either. Investing requires closer diligence on your part, so use these ratings as a launching pad for your own research.

A heavy burden
Although I've disliked Eastman Kodak's reliance upon a patent portfolio as a basis for rebuilding the company, the recent ruling by the International Trade Commission to re-examine the once iconic camera maker's complaints against Apple (Nasdaq: AAPL) and Research In Motion (Nasdaq: RIMM) has breathed new life into the stock, at least briefly. A potential billion dollar payout would certainly feed its coffers, but I still prefer to look at Kodak as a zombie that doesn't yet realize it's dead.

Nokia is also going after Apple and has some seemingly strong arguments in favor of its patents, but the trade body sided with Apple. Yet like Kodak, Nokia is facing a future that is a shell of its former self, left making little more than commoditized hardware.

With even HTC having surpassed Nokia in size, CAPS member andao thinks the Finnish company hasn't exhibited any innovation to distinguish it from its rivals:

Nokia isn't nearly as fast on tech as some of the other big players like Samsung, HTC, Apple, and Motorola. I love my Nokia phone and I expect there will be fans who stick with them through the transition to Windows phone software, but I don't see what they can possibly do to distinguish themselves positively from the aforementioned phone companies. Unless they have a price point to die for, I think they're a sinking ship.

But for a company needing to rely on its patent portfolio for any chance at a future, Kodak is taking an interesting route. Image sensors were deemed an important component of its business, but it just sold a portfolio of 850 image sensor patents to OmniVision Technology (Nasdaq: OVTI). While that move may allow Kodak to survive, it hardly seems like a picture of company that's thriving.

All-Star anthrobabble is also none too thrilled about the path Kodak has chosen: "Re-upping on this doomed dinosaur-too late to adjust to a non-filmed world, using litigation payments as a revenue stream is a not a solid business model."

While you're adding Nokia to your watchlist to see whether it can dial up growth again, let us know on the Eastman Kodak CAPS page whether this is really a flash of brilliance by the one-time camera king.

Still a lot of money
Having produced the first new drug treatment for lupus in 50 years, Human Genome Sciences should be attracting a lot more bullish sentiment from investors, or so you'd think. But with plenty of caveats for the drug's use -- certain indications are compatible with the drug and other populations probably are not right for it -- the biotech may not receive the full market opportunity.

Yet with potential sales estimated at as much as $7 billion, even if Eli Lilly or Immunomedics (Nasdaq: IMMU) come to market with their own therapies it still leave plenty of upside for HGS.

Highly rated CAPS All-Star zzlangerhans is one however who believes there's still a lot of room for it to move higher still.

The company just broadened their pipeline with a partnership for a developmental cancer drug, reducing the likelihood of a buyout in the near term, but another strong positive catalyst of European approval looms in the second half of this year.

Add the biotech to the Fool's free portfolio tracker and keep an eye on whether it will expand to fill the gap.

What's wrong with that?
It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

Sign up today for the completely free service, and tell us which side of the street will be the ultimate winner.